» Articles » PMID: 29387042

Type 2 Diabetes Mellitus and Cardiovascular Disease: Genetic and Epigenetic Links

Overview
Specialty Endocrinology
Date 2018 Feb 2
PMID 29387042
Citations 153
Authors
Affiliations
Soon will be listed here.
Abstract

Type 2 diabetes mellitus (DM) is a common metabolic disorder predisposing to diabetic cardiomyopathy and atherosclerotic cardiovascular disease (CVD), which could lead to heart failure through a variety of mechanisms, including myocardial infarction and chronic pressure overload. Pathogenetic mechanisms, mainly linked to hyperglycemia and chronic sustained hyperinsulinemia, include changes in metabolic profiles, intracellular signaling pathways, energy production, redox status, increased susceptibility to ischemia, and extracellular matrix remodeling. The close relationship between type 2 DM and CVD has led to the common soil hypothesis, postulating that both conditions share common genetic and environmental factors influencing this association. However, although the common risk factors of both CVD and type 2 DM, such as obesity, insulin resistance, dyslipidemia, inflammation, and thrombophilia, can be identified in the majority of affected patients, less is known about how these factors influence both conditions, so that efforts are still needed for a more comprehensive understanding of this relationship. The genetic, epigenetic, and environmental backgrounds of both type 2 DM and CVD have been more recently studied and updated. However, the underlying pathogenetic mechanisms have seldom been investigated within the broader shared background, but rather studied in the specific context of type 2 DM or CVD, separately. As the precise pathophysiological links between type 2 DM and CVD are not entirely understood and many aspects still require elucidation, an integrated description of the genetic, epigenetic, and environmental influences involved in the concomitant development of both diseases is of paramount importance to shed new light on the interlinks between type 2 DM and CVD. This review addresses the current knowledge of overlapping genetic and epigenetic aspects in type 2 DM and CVD, including microRNAs and long non-coding RNAs, whose abnormal regulation has been implicated in both disease conditions, either etiologically or as cause for their progression. Understanding the links between these disorders may help to drive future research toward an integrated pathophysiological approach and to provide future directions in the field.

Citing Articles

Exploring the Cardiovascular Benefits of Extra Virgin Olive Oil: Insights into Mechanisms and Therapeutic Potential.

Milena E, Maurizio M Biomolecules. 2025; 15(2).

PMID: 40001586 PMC: 11852600. DOI: 10.3390/biom15020284.


Association Between Different Thyroid-Stimulating Hormone Levels and Macrovascular Complications in Subclinical Hypothyroidism Patients With Type 2 Diabetes Mellitus.

Mahmud N, Jagdewsing D, Ji X, Harine I, Adjibou B, Fahmy N Cureus. 2025; 17(2):e79186.

PMID: 39967822 PMC: 11832303. DOI: 10.7759/cureus.79186.


Association of glucose to lymphocyte ratio with the risk of death in patients with atherosclerotic cardiovascular disease.

Lei J, Duan W, Yao X, Hu Z, Fan H, Liu Y Sci Rep. 2025; 15(1):3861.

PMID: 39890934 PMC: 11785984. DOI: 10.1038/s41598-025-87260-9.


Integrated analysis of long non‑coding RNA megacluster, microRNA‑132 and microRNA‑133a and their implications for cardiovascular risk and kidney failure progression in diabetic patients.

AbdElgayed G, Hosni A, Abdel-Moneim A, Malik A, Zaky M, Hasona N Exp Ther Med. 2025; 29(2):35.

PMID: 39776891 PMC: 11705225. DOI: 10.3892/etm.2024.12785.


The Implication of NT-proBNP in the Assessment of the Clinical Phenotype of Patients with Type 2 Diabetes Mellitus, Without Established Cardiovascular Disease.

Gastouniotis I, Fragoulis C, Antonopoulos A, Kouroutzoglou A, Noutsou M, Thanopoulou A Biomedicines. 2025; 12(12.

PMID: 39767625 PMC: 11727635. DOI: 10.3390/biomedicines12122718.


References
1.
Gareri C, Iaconetti C, Sorrentino S, Covello C, De Rosa S, Indolfi C . miR-125a-5p Modulates Phenotypic Switch of Vascular Smooth Muscle Cells by Targeting ETS-1. J Mol Biol. 2017; 429(12):1817-1828. DOI: 10.1016/j.jmb.2017.05.008. View

2.
Bray P, McKenzie S, Edelstein L, Nagalla S, Delgrosso K, Ertel A . The complex transcriptional landscape of the anucleate human platelet. BMC Genomics. 2013; 14:1. PMC: 3722126. DOI: 10.1186/1471-2164-14-1. View

3.
Liu C, Mou S, Pan C . The FTO gene rs9939609 polymorphism predicts risk of cardiovascular disease: a systematic review and meta-analysis. PLoS One. 2013; 8(8):e71901. PMC: 3747067. DOI: 10.1371/journal.pone.0071901. View

4.
Grundy S . Pre-diabetes, metabolic syndrome, and cardiovascular risk. J Am Coll Cardiol. 2012; 59(7):635-43. DOI: 10.1016/j.jacc.2011.08.080. View

5.
Adams J, Cox A, Freedman B, Langefeld C, Carr J, Bowden D . Genetic analysis of haptoglobin polymorphisms with cardiovascular disease and type 2 diabetes in the Diabetes Heart Study. Cardiovasc Diabetol. 2013; 12:31. PMC: 3576297. DOI: 10.1186/1475-2840-12-31. View